Inhibiting Phosphocreatine Dependent Energetic Pathway in RAS-Driven Colorectal Cancer by Blocking the SLC6A8 Creatine Transporter by Ompenaclib
Time: 3:45 pm
day: Day Two
Details:
• CKB overexpression pathway in RAS mutated mCRC as a therapeutic target
• Ompenaclib – an oral small molecule blocking SLC 6A8 transport of phosphocreatine
• Pre-clinical and clinical data of ompenaclib activity in RAS mutated mCRC
